
3.68 Delayed Data As of Dec 05 | ![]() Today’s Change | 1.21 Today|||52-Week Range 7.10 | -27.42% Year-to-Date |
Here's Why ImmunityBio (IBRX) Is a Great 'Buy the Bottom' Stock Now Dec 04 / Zacks.com - Paid Partner Content | ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden Cross Nov 27 / Zacks.com - Paid Partner Content |
Previous close | 3.72 |
Today’s open | 3.71 |
Day’s range | 3.61 - 3.79 |
Volume | 73,825 |
Average volume (3 months) | 4,595,840 |
Market cap | $2.5B |
Earnings growth (last year) | -16.91% |
Earnings growth (this year) | -- |
Earnings growth (next 5 years) | -47.93% |
Revenue growth (last year) | -74.30% |
P/E ratio | NM |
Price/Sales | 8,447.90 |
Price/Book | -- |
Today’s change | Today’s % change | |
---|---|---|
ARWRArrowhead Pharmaceut... | -1.51 | -6.06% |
AXSMAxsome Therapeutics ... | +1.19 | +1.76% |
---- | ||
DNLIDenali Therapeutics ... | -0.23 | -1.23% |
Next reporting date | February 27, 2024 |
EPS forecast (this quarter) | -$0.24 |
Annual revenue (last year) | $240.0K |
Annual profit (last year) | -$416.6M |
Net profit margin | -173,569.58% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters San Diego, California |